NCT00681889

Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Reza Dana, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Detailed description

This is an open label, single site, uncontrolled, single group assignment, safety/efficacy, Phase I study of topical administered ranibizumab in subjects with corneal neovascularization. Ten eyes of patients with corneal neovascularization will be recruited. Patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus will be considered.

Conditions

• Corneal Neovascularization

Interventions

Type	Name	Description
DRUG	Ranibizumab	10 Patients will receive treatment (Ranibizumab)

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-09-01
• Completion: 2010-09-01
• First posted: 2008-05-21
• Last updated: 2012-11-08
• Results posted: 2012-11-08

Locations

1 site across 1 country: United States